Barbara E Bierer

Barbara Emily Bierer, MD

Professor of Medicine (Pediatrics), HMS
Member, HMS Center for Bioethics

Barbara Bierer, MD is a Professor of Medicine (Pediatrics) at Harvard Medical School (HMS), and a hematologist/oncologist at the Brigham and Women's Hospital (BWH). She received her MD from HMS. She is the director of the Regulatory Foundations, Law and Ethics Program of the Harvard Catalyst, the Harvard Clinical and Translational Science Award, and the director of regulatory policy, SMART IRB. Dr. Bierer co-founded and now leads the Multi-Regional Clinical Trials Center of BWH and Harvard (MRCT Center), a University-wide and collaborative effort to improve the ethics, conduct, and regulatory environment for multi-site, multi-national clinical trials. She is a co-founder of COVID-19 Collaboration Platform, a platform for cooperation in research. In 2017, the MRCT Center launched the non-profit Vivli, a global clinical research data sharing platform. From 2003-2014, she served as Senior Vice President, Research, at BWH and was the institutional official for human subjects and animal research, for biosafety and for research integrity at the BWH. She initiated the Brigham Research Institute and the Innovation Hub (iHub), a focus for entrepreneurship and innovation. Dr. Bierer established and directed the Center for Faculty Development and Diversity at the BWH; for these efforts, she was the first recipient of the HMS Harold Amos Faculty Diversity Award.

Publications View
Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin.
Authors: Authors: Bierer BE, Mattila PS, Standaert RF, Herzenberg LA, Burakoff SJ, Crabtree G, Schreiber SL.
Proc Natl Acad Sci U S A
View full abstract on Pubmed
The effect of desferrithiocin, an oral iron chelator, on T-cell function.
Authors: Authors: Bierer BE, Nathan DG.
Blood
View full abstract on Pubmed
Probing immunosuppressant action with a nonnatural immunophilin ligand.
Authors: Authors: Bierer BE, Somers PK, Wandless TJ, Burakoff SJ, Schreiber SL.
Science
View full abstract on Pubmed
Mechanisms of immunosuppression by FK506. Preservation of T cell transmembrane signal transduction.
Authors: Authors: Bierer BE, Schreiber SL, Burakoff SJ.
Transplantation
View full abstract on Pubmed
Functional CD2 mutants unable to bind to, or be stimulated by, LFA-3.
Authors: Authors: Wolff HL, Burakoff SJ, Bierer BE.
J Immunol
View full abstract on Pubmed
Partial deletions of the cytoplasmic domain of CD2 result in a partial defect in signal transduction.
Authors: Authors: Bierer BE, Bogart RE, Burakoff SJ.
J Immunol
View full abstract on Pubmed
Depletion of bone marrow T-lymphocytes with an anti-CD5 monoclonal immunotoxin (ST-1 immunotoxin): effective prophylaxis for graft-versus-host disease.
Authors: Authors: Antin JH, Bierer BE, Smith BR, Guinan EC, Provost MM, Ferrara J, Macklis RM, Tarbell NJ, Blythman H, Bouloux C, et al.
Prog Clin Biol Res
View full abstract on Pubmed
T-lymphocyte activation: the biology and function of CD2 and CD4.
Authors: Authors: Bierer BE, Burakoff SJ.
Immunol Rev
View full abstract on Pubmed
A monoclonal antibody to LFA-3, the CD2 ligand, specifically immobilizes major histocompatibility complex proteins.
Authors: Authors: Bierer BE, Golan DE, Brown CS, Herrmann SH, Burakoff SJ.
Eur J Immunol
View full abstract on Pubmed
A large proportion of T lymphocytes lack CD5 expression after bone marrow transplantation.
Authors: Authors: Bierer BE, Burakoff SJ, Smith BR.
Blood
View full abstract on Pubmed